Mallinckrodt Stock Target Price - $20
It has taken too much time but now the truth is out about Mallinckrodt (NYSE:MNK). The newly published Medicare dashboard proves that:
1. As insurance companies have clamped down on reimbursement, tax-inverted Mallinckrodt has dug deeper into the pockets of taxpayer-funded Medicare to peddle its medically unproven Acthar
2. The CEO of MNK has committed FRAUD by lying to the investing public about the company's dependence on the Medicare system.
3. Acthar is now THE MOST EXPENSIVE drug reimbursed by Medicare.
This will soon end and MNK will trade at $20 a share.